HomeCompareCTXRW vs CHD

CTXRW vs CHD: Dividend Comparison 2026

CTXRW yields 1387.93% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTXRW wins by $346908156.07M in total portfolio value
10 years
CTXRW
CTXRW
● Live price
1387.93%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$346908156.10M
Annual income
$303,843,436,712,884.44
Full CTXRW calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — CTXRW vs CHD

📍 CTXRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTXRWCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTXRW + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTXRW pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTXRW
Annual income on $10K today (after 15% tax)
$117,973.63/yr
After 10yr DRIP, annual income (after tax)
$258,266,921,205,951.75/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, CTXRW beats the other by $258,266,921,204,853.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTXRW + CHD for your $10,000?

CTXRW: 50%CHD: 50%
100% CHD50/50100% CTXRW
Portfolio after 10yr
$173454078.06M
Annual income
$151,921,718,357,088.47/yr
Blended yield
87.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

CTXRW
No analyst data
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTXRW buys
0
CHD buys
0
No recent congressional trades found for CTXRW or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTXRWCHD
Forward yield1387.93%1.27%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$346908156.10M$26.4K
Annual income after 10y$303,843,436,712,884.44$1,292.51
Total dividends collected$343747776.19M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CTXRW vs CHD ($10,000, DRIP)

YearCTXRW PortfolioCTXRW Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$149,493$138,792.51$10,856$156.32+$138.6KCTXRW
2$2,099,063$1,939,106.48$11,811$195.24+$2.09MCTXRW
3$27,692,262$25,446,263.94$12,883$244.38+$27.68MCTXRW
4$343,373,046$313,742,325.46$14,091$306.64+$343.36MCTXRW
5$4,003,185,043$3,635,775,884.26$15,463$385.88+$4003.17MCTXRW
6$43,897,781,482$39,614,373,485.65$17,033$487.17+$43897.76MCTXRW
7$452,951,824,425$405,981,198,239.62$18,843$617.36+$452951.81MCTXRW
8$4,399,656,810,870$3,914,998,358,735.43$20,947$785.72+$4399656.79MCTXRW
9$40,247,401,294,059$35,539,768,506,427.31$23,419$1,004.91+$40247401.27MCTXRW
10$346,908,156,097,527$303,843,436,712,884.44$26,350$1,292.51+$346908156.07MCTXRW

CTXRW vs CHD: Complete Analysis 2026

CTXRWStock

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Full CTXRW Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this CTXRW vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTXRW vs SCHDCTXRW vs JEPICTXRW vs OCTXRW vs KOCTXRW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.